Bringing the clinical experience with anakinra to the patient

Rheumatology

Volumn 42, Issue SUPPL. 2, 2003, Pages

  Cohen, Stanley B ^b   Rubbert, A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b St Paul University Medical Center   (United States)

Author keywords

Anakinra; Clinical experience; Compliance; IL 1 receptor antagonist; Patient expectation; Patient reported outcomes; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; SIALOGLYCOPROTEIN;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DATA ANALYSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDEMA; EUROPEAN UNION; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; INFECTION; PATIENT CARE; PHYSICAL ACTIVITY; PHYSICAL DISABILITY; PHYSICIAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK BENEFIT ANALYSIS; SKIN BRUISING; SYMPTOMATOLOGY; UNITED STATES; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 15344351018     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
2. Amgen Inc. Kineret® (anakinra) briefing information, 16 August, 2001. http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3779b1_01_amgen.pdf
3. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant interleukin-1 receptor antagonist, in combination with methotrexate. Results of a twenty-four-week, multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
4. Cohen SB, Moreland LW, Cush JJ et al. Kineret™ (anakinra) (recombinant interleukin-1 receptor antagonist): a large placebo controlled efficacy trial of Kineret™ in patients with erosive rheumatoid arthritis disease. [Abstract] Ann Rheum Dis 2002;61(Suppl. 1):173.
5. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuI1-1ra), in patients with rheumatoid arthritis. A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003;48:927-34.
6. Jiang Y, Genant HK, Watt I et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
7. Cohen S, Smolen J, Tugwell P, Crawford B. Patient-based functional measures of drug treatment in rheumatoid arthritis trials are not susceptible to placebo effect. [Abstract] Arthritis Rheum 2000;43(Suppl. 9):1330.
8. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159:2542-50.
9. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
10. Cohen S, Nakelsky S, Badamgarav E et al. The impact of Kineret™ (anakinra) therapy on patient-reported outcomes in rheumatoid arthritis. [Abstract] Ann Rheum Dis 2002;61(Suppl. 1):338.
11. Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ. Lawrence Erlbaum; 1988.
12. Emery P, Woolley JM, Chan WW. Improvement in health-related quality of life from anakinra therapy in patients with rheumatoid arthritis not using DMARDs. [Abstract] Ann Rheum Dis 2001;60(Suppl. 1):276.
13. Bresnihan B, Chan WW, Woolley JM. Anakinra increases days of work and domestic activity in patients with rheumatoid arthritis. [Abstract] Ann Rheum Dis 2001;60(Suppl. 1): 275.
14. Bresnihan B, Chan WW, Woolley JM. Productivity improvement in patients with rheumatoid arthritis receiving anakinra treatment. [Abstract] Ann Rheum Dis 2002;61(Suppl. 1):182.
15. Amgen Europe BV. Kineret® (anakinra) [summary of product characteristics]; 2001.